Ranbaxy Laboratories
Overall Rating:  [5/5]Total Votes [ 9 ] |
|
Ranbaxy Laboratories Limited was incorporated in 1961 and began operations in 1973. Ranbaxy is an international pharmaceuticals company with its headquarters in India and engages in research-based production of affordable and high-quality generic medicines.
Ranbaxy Laboratories has already made a mark in the global markets and has a presence in 49 countries. It also reached a sales figure of USD 1339 million in 2006. The top contributors towards this sales figure were North America at USD 391 million, Europe at USD 332 million, and Asia at USD 260 million.
The core aspect of the Ranbaxy business has been the Research and Development. Breakthrough research has been taking place through a group of 1200 expert scientists at its Research and Development Center which was established in 1994. Innovative formulations have been an outcome of expert endeavors through New Chemical Entity (NCE), and Novel Drug Delivery System (NDDS).
Ranbaxy research areas for Drug Discovery and Development include metabolic diseases, inflammatory/respiratory, oncology, and anti-infectives. Ranbaxy Drug Discovery and Development had been initiated through alliance with GlaxoSmithKline Plc. Ranbaxy drugs have excelled in Orthopedics, Respiratory Cardiovasculars, Urology, Central, Dermatology, Nutritionals, and Nervous System segments.
With a profound impact on the chronic and lifestyle disease segments, Ranbaxy's top 20 pharmaceuticals has brought in revenues of USD 600 million. Following are the top 10 drugs manufactured by Ranbaxy:
Ranbaxy Laboratories Limited has excelled in its endeavor in drug research and manufacture, providing quality products not only at par with global markets but also facilitating the same.
Last Updated on 1/4/2012
The core aspect of the Ranbaxy business has been the Research and Development. Breakthrough research has been taking place through a group of 1200 expert scientists at its Research and Development Center which was established in 1994. Innovative formulations have been an outcome of expert endeavors through New Chemical Entity (NCE), and Novel Drug Delivery System (NDDS).
Ranbaxy research areas for Drug Discovery and Development include metabolic diseases, inflammatory/respiratory, oncology, and anti-infectives. Ranbaxy Drug Discovery and Development had been initiated through alliance with GlaxoSmithKline Plc. Ranbaxy drugs have excelled in Orthopedics, Respiratory Cardiovasculars, Urology, Central, Dermatology, Nutritionals, and Nervous System segments.
| Latest Financial Figures | (Figures in Rs. Crores) |
|---|---|
| ET 500 Rank(2011) | 82 |
| Industry | Pharmaceuticals |
| Turnover | 9239.16 |
| Profit after Tax(PAT) | 758.08 |
| MCAP (Market Capitalization) | 21480 |
| Assets | 9393.11 |
With a profound impact on the chronic and lifestyle disease segments, Ranbaxy's top 20 pharmaceuticals has brought in revenues of USD 600 million. Following are the top 10 drugs manufactured by Ranbaxy:
- Simvastatin
- Amoxy+Clav Potas Com
- Amoxycillin
- Ciprofloxacin
- Isotretinon
- Cephalexin
- Ketorolac Tromethamine
- Cefaclor
- Clarithromycin
- Cefuroxime Axetil
Ranbaxy Laboratories Limited has excelled in its endeavor in drug research and manufacture, providing quality products not only at par with global markets but also facilitating the same.
Last Updated on 1/4/2012
List of R Letter Companies
